Novartis gains EU approval for MS treatment Mayzent
The European Commission approved Novartis' Mayzent, or siponimod, as a treatment for adults with active secondary progressive multiple sclerosis, providing this patient subpopulation a new treatment option. PMLive (UK) (1/21)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!